US Pharmaceutical company Neurelis, which recently submitted an NDA for Valtoco diazepam nasal spray, has acquired Aegis Therapeutics and its Intravail transmucosal absorption technology, a component of the Valtoco formulation.
In addition to Intravail, Aegis Therapeutics offers two other excipients that can be used in nasal formulations, ProTek and Aegis Hydrogels, and the company has patented numerous nasal formulations using its products, including octreotide, parathyroid hormone, and triptans.
In its announcement, Neurelis cited several of Aegis’s key licensing agreements, with Dr. Reddy’s subsidiary Promius Pharma, which submitted an NDA for an intranasal sumatriptan based on Intravail technology earlier this year, and with Opiant, which announced in June 2017 that it had licensed the Intravail technology from Aegis for use in its intranasal opiate antagonists.
Neurelis President and CEO Craig Chambliss commented, “We have been very impressed by the performance of Intravail in Valtoco as well as other licensed programs initiated by Aegis. Intravail is a unique technology platform that we intend to fully integrate into our robust product pipeline which is targeted to address significant unmet needs in neurology.”
Neurelis is currently developing two intranasal lorezepam candidates, NRL-2 for the treatment of acute anxiety and NRL-3 for the treatment of epileptic seizures.
Aegis Therapeutics CEO Ed Maggio said, “We are thankful to have been a part of the important work in progressing these programs with our strategic partners over the years. In the coming months, we have the potential of seeing the first two products incorporating the Intravail technology approved by the FDA. Given our longstanding relationship with Neurelis and their appreciation for the value of Intravail, we are excited for the next chapters of success with these novel technologies.”
Read the Neurelis press release.
